Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery.

Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J.

Sci Rep. 2019 Jun 25;9(1):9251. doi: 10.1038/s41598-019-45461-z.

2.

Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome.

Lucas M, Deshpande P, James I, Rauch A, Pfafferott K, Gaylard E, Merani S, Plauzolles A, Lucas A, McDonnell W, Kalams S, Pilkinton M, Chastain C, Barnett L, Prosser A, Mallal S, Fitzmaurice K, Drummer H, Ansari MA, Pedergnana V, Barnes E, John M, Kelleher D, Klenerman P, Gaudieri S.

Sci Rep. 2018 May 8;8(1):7224. doi: 10.1038/s41598-018-25559-6.

3.

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.

Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J.

Sci Rep. 2018 Apr 24;8(1):6483. doi: 10.1038/s41598-018-24762-9.

4.

Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion.

Narasimhulu VGS, Bellamy-McIntyre AK, Laumaea AE, Lay CS, Harrison DN, King HAD, Drummer HE, Poumbourios P.

J Biol Chem. 2018 Apr 20;293(16):6099-6120. doi: 10.1074/jbc.RA117.000537. Epub 2018 Mar 1.

5.

Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists.

Christiansen D, Earnest-Silveira L, Chua B, Boo I, Drummer HE, Grubor-Bauk B, Gowans EJ, Jackson DC, Torresi J.

Viral Immunol. 2018 May;31(4):338-343. doi: 10.1089/vim.2017.0182. Epub 2018 Feb 28.

PMID:
29489437
6.

Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.

Gu J, Hardy J, Boo I, Vietheer P, McCaffrey K, Alhammad Y, Chopra A, Gaudieri S, Poumbourios P, Coulibaly F, Drummer HE.

J Virol. 2018 Apr 13;92(9). pii: e02066-17. doi: 10.1128/JVI.02066-17. Print 2018 May 1.

7.

A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.

Grove J, Hu K, Farquhar MJ, Goodall M, Walker L, Jamshad M, Drummer HE, Bill RM, Balfe P, McKeating JA.

Wellcome Open Res. 2017 Sep 7;2:82. doi: 10.12688/wellcomeopenres.12058.1. eCollection 2017.

8.

An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.

McCaffrey K, Boo I, Owczarek CM, Hardy MP, Perugini MA, Fabri L, Scotney P, Poumbourios P, Drummer HE.

J Virol. 2017 Feb 14;91(5). pii: e01668-16. doi: 10.1128/JVI.01668-16. Print 2017 Mar 1.

9.

The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.

Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P, Drummer HE.

Hepatology. 2017 Apr;65(4):1117-1131. doi: 10.1002/hep.28989. Epub 2017 Feb 14.

10.

The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact.

Boeuf P, Drummer HE, Richards JS, Scoullar MJ, Beeson JG.

BMC Med. 2016 Aug 3;14(1):112. doi: 10.1186/s12916-016-0660-0. Review.

11.

HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.

Saleh S, Lu HK, Evans V, Harisson D, Zhou J, Jaworowski A, Sallmann G, Cheong KY, Mota TM, Tennakoon S, Angelovich TA, Anderson J, Harman A, Cunningham A, Gray L, Churchill M, Mak J, Drummer H, Vatakis DN, Lewin SR, Cameron PU.

Retrovirology. 2016 Jul 26;13(1):49. doi: 10.1186/s12977-016-0284-7.

12.

The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?

Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P.

PLoS One. 2016 May 25;11(5):e0156213. doi: 10.1371/journal.pone.0156213. eCollection 2016.

13.

Calsyntenin-1 mediates hepatitis C virus replication.

Awan Z, Tay ES, Eyre NS, Wu LE, Beard MR, Boo I, Drummer HE, George J, Douglas MW.

J Gen Virol. 2016 Aug;97(8):1877-87. doi: 10.1099/jgv.0.000511. Epub 2016 May 24.

PMID:
27221318
14.

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line.

Earnest-Silveira L, Chua B, Chin R, Christiansen D, Johnson D, Herrmann S, Ralph SA, Vercauteren K, Mesalam A, Meuleman P, Das S, Boo I, Drummer H, Bock CT, Gowans EJ, Jackson DC, Torresi J.

J Gen Virol. 2016 Aug;97(8):1865-76. doi: 10.1099/jgv.0.000493. Epub 2016 May 4.

PMID:
27147296
15.

Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.

Alhammad Y, Gu J, Boo I, Harrison D, McCaffrey K, Vietheer PT, Edwards S, Quinn C, Coulibaly F, Poumbourios P, Drummer HE.

J Virol. 2015 Dec;89(24):12245-61. doi: 10.1128/JVI.02070-15. Epub 2015 Sep 16.

16.

The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.

Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M.

BMC Med. 2015 Aug 20;13:198. doi: 10.1186/s12916-015-0440-2.

17.
18.

Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection.

Alhammad YM, Maharajh S, Butcher R, Eden JS, White PA, Poumbourios P, Drummer HE.

PLoS One. 2015 May 13;10(5):e0126397. doi: 10.1371/journal.pone.0126397. eCollection 2015.

19.

Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.

Drummer HE.

Front Microbiol. 2014 Jul 3;5:329. doi: 10.3389/fmicb.2014.00329. eCollection 2014. Review.

20.
21.

A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.

Beard MR, Ffrench R, Gowans EJ, Helbig KJ, Eyre NM, Douglas MM, Grebely J, Ahlenstiel G, Locarnini S, George J, Shackel NA, White PA, Thompson AJ, Drummer HE.

Gastroenterology. 2014 Jul;147(1):e1-4. doi: 10.1053/j.gastro.2014.05.022. Epub 2014 May 23. No abstract available.

PMID:
24861641
22.

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.

Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M.

Hepat Mon. 2014 Jan 8;14(1):e14678. doi: 10.5812/hepatmon.14678. eCollection 2014 Jan.

23.

High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.

Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M.

PLoS One. 2013 Nov 7;8(11):e80216. doi: 10.1371/journal.pone.0080216. eCollection 2013.

24.

Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41.

Khasawneh AI, Laumaea A, Harrison DN, Bellamy-McIntyre AK, Drummer HE, Poumbourios P.

Retrovirology. 2013 Apr 23;10:44. doi: 10.1186/1742-4690-10-44.

25.

Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.

Drummer HE, Hill MK, Maerz AL, Wood S, Ramsland PA, Mak J, Poumbourios P.

PLoS Pathog. 2013;9(4):e1003218. doi: 10.1371/journal.ppat.1003218. Epub 2013 Apr 4.

26.

Identification of specific regions in hepatitis C virus core, NS2 and NS5A that genetically interact with p7 and co-ordinate infectious virus production.

Gouklani H, Beyer C, Drummer H, Gowans EJ, Netter HJ, Haqshenas G.

J Viral Hepat. 2013 Apr;20(4):e66-71. doi: 10.1111/jvh.12004. Epub 2012 Sep 30.

PMID:
23490391
27.

In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface.

Davis C, Harris HJ, Hu K, Drummer HE, McKeating JA, Mullins JG, Balfe P.

Cell Microbiol. 2012 Dec;14(12):1892-903. doi: 10.1111/cmi.12008. Epub 2012 Sep 25.

28.

Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis.

Gouklani H, Bull RA, Beyer C, Coulibaly F, Gowans EJ, Drummer HE, Netter HJ, White PA, Haqshenas G.

J Virol. 2012 May;86(9):5080-8. doi: 10.1128/JVI.07089-11. Epub 2012 Feb 15.

29.

Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function.

McCaffrey K, Boo I, Tewierek K, Edmunds ML, Poumbourios P, Drummer HE.

J Virol. 2012 Apr;86(7):3961-74. doi: 10.1128/JVI.05396-11. Epub 2012 Jan 25.

30.

Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2.

Boo I, teWierik K, Douam F, Lavillette D, Poumbourios P, Drummer HE.

Biochem J. 2012 Apr 1;443(1):85-94. doi: 10.1042/BJ20110868.

PMID:
22240035
31.

Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Lay CS, Ludlow LE, Stapleton D, Bellamy-McIntyre AK, Ramsland PA, Drummer HE, Poumbourios P.

J Biol Chem. 2011 Dec 2;286(48):41331-43. doi: 10.1074/jbc.M111.299826. Epub 2011 Oct 5.

32.

Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry.

Fraser J, Boo I, Poumbourios P, Drummer HE.

J Biol Chem. 2011 Sep 16;286(37):31984-92. doi: 10.1074/jbc.M111.269605. Epub 2011 Jul 15.

33.

The SR-BI partner PDZK1 facilitates hepatitis C virus entry.

Eyre NS, Drummer HE, Beard MR.

PLoS Pathog. 2010 Oct 7;6(10):e1001130. doi: 10.1371/journal.ppat.1001130.

34.

The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity.

McCaffrey K, Gouklani H, Boo I, Poumbourios P, Drummer HE.

J Gen Virol. 2011 Jan;92(Pt 1):112-21. doi: 10.1099/vir.0.026385-0. Epub 2010 Oct 6.

PMID:
20926639
35.

Claudin association with CD81 defines hepatitis C virus entry.

Harris HJ, Davis C, Mullins JG, Hu K, Goodall M, Farquhar MJ, Mee CJ, McCaffrey K, Young S, Drummer H, Balfe P, McKeating JA.

J Biol Chem. 2010 Jul 2;285(27):21092-102. doi: 10.1074/jbc.M110.104836. Epub 2010 Apr 7.

36.

Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function.

Bellamy-McIntyre AK, Bär S, Ludlow L, Drummer HE, Poumbourios P.

Biochem Biophys Res Commun. 2010 Apr 16;394(4):904-8. doi: 10.1016/j.bbrc.2010.03.071. Epub 2010 Mar 15.

PMID:
20230797
37.

TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus.

Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Tracy S, Holdsworth R, Bowden S, Jackson D, Hellard M, Torresi J, McCluskey J.

Immunol Cell Biol. 2009 Aug-Sep;87(6):464-72. doi: 10.1038/icb.2009.24. Epub 2009 May 12.

PMID:
19434069
38.

Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix.

Cheong WS, Drummer HE, Netter HJ.

J Virol Methods. 2009 Jun;158(1-2):35-40. doi: 10.1016/j.jviromet.2009.01.015. Epub 2009 Feb 2.

PMID:
19189849
39.

High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.

Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H, Hellard M.

Hepatology. 2008 Dec;48(6):1746-52. doi: 10.1002/hep.22534.

PMID:
18844233
40.

Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.

Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA.

J Virol. 2008 Dec;82(24):12020-9. doi: 10.1128/JVI.01569-08. Epub 2008 Oct 1.

41.
42.
43.

Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.

McCaffrey K, Boo I, Poumbourios P, Drummer HE.

J Virol. 2007 Sep;81(17):9584-90. Epub 2007 Jun 20.

44.

An N-terminal glycine-rich sequence contributes to retrovirus trimer of hairpins stability.

Wilson KA, Maerz AL, Bär S, Drummer HE, Poumbourios P.

Biochem Biophys Res Commun. 2007 Aug 10;359(4):1037-43. Epub 2007 Jun 11.

PMID:
17577584
45.

Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.

Boo I, Fischer AE, Johnson D, Chin R, Giourouki M, Bharadwaj M, Bowden S, Torresi J, Drummer H.

J Clin Virol. 2007 Aug;39(4):288-94. Epub 2007 Jun 14.

PMID:
17569577
46.

Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion.

Bellamy-McIntyre AK, Lay CS, Baär S, Maerz AL, Talbo GH, Drummer HE, Poumbourios P.

J Biol Chem. 2007 Aug 10;282(32):23104-16. Epub 2007 May 25.

47.

A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus.

Torresi J, Stock OM, Fischer AE, Grollo L, Drummer H, Boo I, Zeng W, Earnest-Silveira L, Jackson DC.

Hepatology. 2007 Apr;45(4):911-20.

PMID:
17393515
48.
49.

Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.

Grollo L, Torresi J, Drummer H, Zeng W, Williamson N, Jackson DC.

Antivir Ther. 2006;11(8):1005-14.

PMID:
17302370
50.

Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes.

Torresi J, Fischer A, Grollo L, Zeng W, Drummer H, Jackson DC.

Immunol Cell Biol. 2007 Feb-Mar;85(2):169-73. Epub 2007 Jan 23.

PMID:
17242693

Supplemental Content

Loading ...
Support Center